219 related articles for article (PubMed ID: 29807369)
1. Circulating Biomarkers for Cholangiocarcinoma.
Loosen SH; Vucur M; Trautwein C; Roderburg C; Luedde T
Dig Dis; 2018; 36(4):281-288. PubMed ID: 29807369
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
Loosen SH; Roderburg C; Kauertz KL; Pombeiro I; Leyh C; Benz F; Vucur M; Longerich T; Koch A; Braunschweig T; Ulmer TF; Heidenhain C; Tacke F; Binnebösel M; Schmeding M; Trautwein C; Neumann UP; Luedde T
J Hepatol; 2017 Oct; 67(4):749-757. PubMed ID: 28668580
[TBL] [Abstract][Full Text] [Related]
3. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art.
Lang SA; Bednarsch J; Joechle K; Amygdalos I; Czigany Z; Heij L; Ulmer TF; Neumann UP
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):497-510. PubMed ID: 33970740
[No Abstract] [Full Text] [Related]
4. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.
Wang LJ; Zhang KL; Zhang N; Ma XW; Yan SW; Cao DH; Shi SJ
Oncotarget; 2015 Jul; 6(21):18631-40. PubMed ID: 26087181
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma.
Liu CH; Huang Q; Jin ZY; Xie F; Zhu CL; Liu Z; Wang C
J Cancer Res Ther; 2018 Jan; 14(1):220-225. PubMed ID: 29516989
[TBL] [Abstract][Full Text] [Related]
6. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.
Puik JR; Meijer LL; Le Large TY; Prado MM; Frampton AE; Kazemier G; Giovannetti E
Pharmacogenomics; 2017 Sep; 18(14):1343-1358. PubMed ID: 28832247
[TBL] [Abstract][Full Text] [Related]
7. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile.
Wang B; Chen L; Chang HT
Biomark Med; 2016 Jun; 10(6):613-9. PubMed ID: 27232281
[TBL] [Abstract][Full Text] [Related]
8. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma.
Jiang Y; Zheng X; Jiao D; Chen P; Xu Y; Wei H; Qian Y
EBioMedicine; 2019 Feb; 40():422-431. PubMed ID: 30638862
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring.
Wen N; Peng D; Xiong X; Liu G; Nie G; Wang Y; Xu J; Wang S; Yang S; Tian Y; Li B; Lu J; Cheng N
Signal Transduct Target Ther; 2024 May; 9(1):107. PubMed ID: 38697972
[TBL] [Abstract][Full Text] [Related]
10. A Novel Serum Glycobiomarker for Diagnosis and Prognosis of Cholangiocarcinoma Detected by
Teeravirote K; Luang S; Waraasawapati S; Boonsiri P; Wongkham C; Wongkham S; Silsirivanit A
Molecules; 2021 May; 26(9):. PubMed ID: 34066878
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.
Julich-Haertel H; Urban SK; Krawczyk M; Willms A; Jankowski K; Patkowski W; Kruk B; Krasnodębski M; Ligocka J; Schwab R; Richardsen I; Schaaf S; Klein A; Gehlert S; Sänger H; Casper M; Banales JM; Schuppan D; Milkiewicz P; Lammert F; Krawczyk M; Lukacs-Kornek V; Kornek M
J Hepatol; 2017 Aug; 67(2):282-292. PubMed ID: 28267620
[TBL] [Abstract][Full Text] [Related]
12. Exosomal piRNA profiling revealed unique circulating piRNA signatures of cholangiocarcinoma and gallbladder carcinoma.
Gu X; Wang C; Deng H; Qing C; Liu R; Liu S; Xue X
Acta Biochim Biophys Sin (Shanghai); 2020 May; 52(5):475-484. PubMed ID: 32369104
[TBL] [Abstract][Full Text] [Related]
13. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic biomarkers in cholangiocarcinoma.
Macias RIR; Kornek M; Rodrigues PM; Paiva NA; Castro RE; Urban S; Pereira SP; Cadamuro M; Rupp C; Loosen SH; Luedde T; Banales JM
Liver Int; 2019 May; 39 Suppl 1():108-122. PubMed ID: 30843325
[TBL] [Abstract][Full Text] [Related]
15. Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach.
Pattanapairoj S; Silsirivanit A; Muisuk K; Seubwai W; Cha'on U; Vaeteewoottacharn K; Sawanyawisuth K; Chetchotsak D; Wongkham S
Clin Biochem; 2015 Jul; 48(10-11):668-73. PubMed ID: 25863112
[TBL] [Abstract][Full Text] [Related]
16. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
Ettrich TJ; Schwerdel D; Dolnik A; Beuter F; Blätte TJ; Schmidt SA; Stanescu-Siegmund N; Steinacker J; Marienfeld R; Kleger A; Bullinger L; Seufferlein T; Berger AW
Sci Rep; 2019 Sep; 9(1):13261. PubMed ID: 31519967
[TBL] [Abstract][Full Text] [Related]
17. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.
Lin ZY; Liang ZX; Zhuang PL; Chen JW; Cao Y; Yan LX; Yun JP; Xie D; Cai MY
BMC Cancer; 2016 Oct; 16(1):792. PubMed ID: 27733196
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma.
Loosen SH; Lurje G; Wiltberger G; Vucur M; Koch A; Kather JN; Paffenholz P; Tacke F; Ulmer FT; Trautwein C; Luedde T; Neumann UP; Roderburg C
PLoS One; 2019; 14(1):e0210944. PubMed ID: 30653586
[TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma: Present Status and Molecular Aspects of Diagnosis.
Liu XF; Tang K; Sui LL; Xu G
Oncol Res; 2014; 22(4):177-183. PubMed ID: 26351206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
